论文部分内容阅读
目的研究CD24在乳腺浸润性导管癌组织不同模式中的表达及其与临床病理因素的相关性。方法用SP免疫组化染色法检测13例乳腺纤维腺瘤及46例乳腺浸润性导管癌组织中CD24的表达。结果浸润性乳腺导管癌组织中CD24在细胞膜和细胞浆都有表达,阳性率为80.43%;乳腺纤维腺瘤CD24仅在细胞膜上局灶性表达,阳性率为53.85%。CD24在浸润性导管癌中的表达浓度明显高于纤维腺瘤(P<0.05);并与腋窝淋巴结转移正相关(P<0.05);CD24细胞膜表达与雌、孕激素受体阳性表达密切相关(P<0.001),而与患者年龄、肿瘤大小、肿瘤分期、分级、Her-2及p53等因素无相关性(P>0.05)。结论CD24高表达参与乳腺癌的侵袭与转移,CD24细胞膜表达可能与乳腺癌内分泌治疗抵抗作用相关,CD24可作为乳腺不良预后的判断指标之一。
Objective To study the expression of CD24 in different modes of invasive ductal carcinoma of breast and its relationship with clinicopathological factors. Methods SP immunohistochemical staining was used to detect CD24 expression in 13 cases of breast fibroadenoma and 46 cases of invasive ductal breast cancer. Results The positive expression rate of CD24 in the cell membrane and cytoplasm of invasive ductal carcinoma was 80.43%. The positive expression rate of CD24 was only 53.85% in the cell membrane. The expression of CD24 in invasive ductal carcinoma was significantly higher than that in fibroadenoma (P <0.05), and positively correlated with axillary lymph node metastasis (P <0.05). The expression of CD24 was closely related to the positive expression of estrogen and progesterone receptors P <0.001), but not with age, tumor size, tumor stage, grading, Her-2 and p53 (P> 0.05). Conclusion The high expression of CD24 is involved in the invasion and metastasis of breast cancer. The expression of CD24 may be related to the resistance to endocrine therapy in breast cancer. CD24 may serve as a marker for the prognosis of breast cancer.